NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis $1.61 -0.05 (-3.01%) Closing price 05/1/2025 03:59 PM EasternExtended Trading$1.63 +0.02 (+1.18%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mangoceuticals Stock (NASDAQ:MGRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mangoceuticals alerts:Sign Up Key Stats Today's Range$1.60▼$1.6950-Day Range$1.57▼$5.2852-Week Range$1.49▼$16.80Volume94,281 shsAverage Volume272,142 shsMarket Capitalization$8.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More… Mangoceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreMGRX MarketRank™: Mangoceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mangoceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mangoceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mangoceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMangoceuticals has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mangoceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.71% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently decreased by 29.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMangoceuticals does not currently pay a dividend.Dividend GrowthMangoceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.71% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently decreased by 29.32%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.83 News SentimentMangoceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Mangoceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for MGRX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Mangoceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mangoceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mangoceuticals' insider trading history. Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MGRX Stock News HeadlinesMangoceuticals Enters Wellness Pouch Market, Appoints Tim Corkum To Lead New UnitApril 27, 2025 | nasdaq.comMangoceuticals enters into agreement to acquire assets of Smokeless TechnologyApril 27, 2025 | markets.businessinsider.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 2, 2025 | Brownstone Research (Ad)Mangoceuticals Acquires IP to Expand Product LineApril 25, 2025 | tipranks.comMangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch DivisionApril 25, 2025 | globenewswire.comMangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness SolutionsApril 24, 2025 | finance.yahoo.comMangoceuticals Issues Bonus Shares to LeadershipApril 11, 2025 | tipranks.comMangoceuticals Issues Common Stock in Exchange for PreferredMarch 30, 2025 | investing.comSee More Headlines MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed this year? Mangoceuticals' stock was trading at $2.42 at the start of the year. Since then, MGRX stock has decreased by 33.5% and is now trading at $1.61. View the best growth stocks for 2025 here. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) released its quarterly earnings data on Thursday, March, 20th. The company reported ($1.01) EPS for the quarter. The firm had revenue of $0.11 million for the quarter. Mangoceuticals had a negative net margin of 1,237.00% and a negative trailing twelve-month return on equity of 138.00%. When did Mangoceuticals' stock split? Mangoceuticals shares reverse split on the morning of Wednesday, October 16th 2024. The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering on Tuesday, March 21st 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mangoceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mangoceuticals investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), Advanced Micro Devices (AMD). Company Calendar Last Earnings3/20/2025Today5/01/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealthcare Current SymbolNASDAQ:MGRX CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,210,000.00 Net Margins-1,237.00% Pretax Margin-1,237.00% Return on Equity-138.00% Return on Assets-118.88% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$615,873.00 Price / Sales13.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book2.98Miscellaneous Outstanding Shares5,169,000Free Float1,510,000Market Cap$8.32 million OptionableNot Optionable Beta2.41 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:MGRX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.